Nataleen A Albekairy, Reema Abdullah Aldawsari, Sarah Alanazi, Nora Almutairi, Nora AlSayari, Salem Abu Al-Burak, Mona Abubakr Bawazeer, Lama Alfehaid, Mohammad S Shawaqfeh
{"title":"非心脏药物致QTc间期延长的预测分析:一项横断面研究。","authors":"Nataleen A Albekairy, Reema Abdullah Aldawsari, Sarah Alanazi, Nora Almutairi, Nora AlSayari, Salem Abu Al-Burak, Mona Abubakr Bawazeer, Lama Alfehaid, Mohammad S Shawaqfeh","doi":"10.2147/CPAA.S509476","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the real-world impacts of non-cardiac drug-induced QTc interval prolongation and identify associated risk factors in acute care settings.</p><p><strong>Patients and methods: </strong>A cross-sectional study reviewed medical charts of 7,778 patients admitted to tertiary teaching hospitals from January 2016 to December 2022. Patients on CredibleMeds-listed QTc-prolonging non-cardiac drugs were identified, excluding those with congenital long QTc syndrome or on QTc-prolonging cardiac medications. Data collection involved reviewing medication charts and recording demographic and clinical data, including comorbidities and laboratory values. A logistic regression analysis was performed to address confounders, and known risk factors, calculating Odds Ratios (OR) and 95% confidence intervals (CI). Statistical analysis used SPSS Version 21.0, with p < 0.05 indicating significance.</p><p><strong>Results: </strong>Out of 7,778 screened patients, 151 met the inclusion criteria. Among these, 75.5% demonstrated prolonged QTc values. The study identified 42 distinct medications associated with QT interval prolongation, categorized into six therapeutic groups. Proton pump inhibitors (PPIs) were the most common cause of non-cardiac drug-induced QTc interval prolongation, with esomeprazole representing 46.5% of the cases. Antimicrobial medications followed, with azithromycin at 9.6% and piperacillin-tazobactam at 6.1%. The multivariate analysis revealed that heart failure was significantly associated with QTc prolongation odd ratio (OR) 4.98 with 95% confidence interval CI [1.58 to 17.35], while other factors such as age, BMI, and certain comorbidities did not show a statistically significant impact.</p><p><strong>Conclusion: </strong>The findings highlight the significant risk associated with the in-hospital administration of QTc-prolonging non-cardiac medications, particularly among patients with heart failure. Future research should aim to include a larger patient population and employ comprehensive data collection methods across multiple centers to enhance the robustness and generalizability of the findings.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"17 ","pages":"85-96"},"PeriodicalIF":3.1000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085126/pdf/","citationCount":"0","resultStr":"{\"title\":\"Predictive Analysis of Non-Cardiac Drug-Induced QTc Interval Prolongation: A Cross-Sectional Study.\",\"authors\":\"Nataleen A Albekairy, Reema Abdullah Aldawsari, Sarah Alanazi, Nora Almutairi, Nora AlSayari, Salem Abu Al-Burak, Mona Abubakr Bawazeer, Lama Alfehaid, Mohammad S Shawaqfeh\",\"doi\":\"10.2147/CPAA.S509476\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aimed to assess the real-world impacts of non-cardiac drug-induced QTc interval prolongation and identify associated risk factors in acute care settings.</p><p><strong>Patients and methods: </strong>A cross-sectional study reviewed medical charts of 7,778 patients admitted to tertiary teaching hospitals from January 2016 to December 2022. Patients on CredibleMeds-listed QTc-prolonging non-cardiac drugs were identified, excluding those with congenital long QTc syndrome or on QTc-prolonging cardiac medications. Data collection involved reviewing medication charts and recording demographic and clinical data, including comorbidities and laboratory values. A logistic regression analysis was performed to address confounders, and known risk factors, calculating Odds Ratios (OR) and 95% confidence intervals (CI). Statistical analysis used SPSS Version 21.0, with p < 0.05 indicating significance.</p><p><strong>Results: </strong>Out of 7,778 screened patients, 151 met the inclusion criteria. Among these, 75.5% demonstrated prolonged QTc values. The study identified 42 distinct medications associated with QT interval prolongation, categorized into six therapeutic groups. Proton pump inhibitors (PPIs) were the most common cause of non-cardiac drug-induced QTc interval prolongation, with esomeprazole representing 46.5% of the cases. Antimicrobial medications followed, with azithromycin at 9.6% and piperacillin-tazobactam at 6.1%. The multivariate analysis revealed that heart failure was significantly associated with QTc prolongation odd ratio (OR) 4.98 with 95% confidence interval CI [1.58 to 17.35], while other factors such as age, BMI, and certain comorbidities did not show a statistically significant impact.</p><p><strong>Conclusion: </strong>The findings highlight the significant risk associated with the in-hospital administration of QTc-prolonging non-cardiac medications, particularly among patients with heart failure. Future research should aim to include a larger patient population and employ comprehensive data collection methods across multiple centers to enhance the robustness and generalizability of the findings.</p>\",\"PeriodicalId\":10406,\"journal\":{\"name\":\"Clinical Pharmacology : Advances and Applications\",\"volume\":\"17 \",\"pages\":\"85-96\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-05-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085126/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pharmacology : Advances and Applications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/CPAA.S509476\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology : Advances and Applications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CPAA.S509476","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究旨在评估非心脏药物引起的QTc间期延长的实际影响,并确定急性护理环境中的相关危险因素。患者与方法:横断面研究回顾了2016年1月至2022年12月在三级教学医院住院的7778例患者的病历。使用creditblemed列出的延长QTc的非心脏药物的患者被确定,不包括先天性延长QTc综合征或延长QTc的心脏药物。数据收集包括回顾用药图表和记录人口统计学和临床数据,包括合并症和实验室值。进行逻辑回归分析以解决混杂因素和已知危险因素,计算优势比(OR)和95%置信区间(CI)。统计学分析采用SPSS Version 21.0, p < 0.05为差异有统计学意义。结果:在7778例筛查患者中,151例符合纳入标准。其中75.5%表现出延长的QTc值。该研究确定了42种与QT间期延长相关的不同药物,分为6个治疗组。质子泵抑制剂(PPIs)是非心脏药物诱导QTc间期延长的最常见原因,其中埃索美拉唑占46.5%。抗菌药物紧随其后,阿奇霉素占9.6%,哌拉西林-他唑巴坦占6.1%。多因素分析显示心力衰竭与QTc延长的奇比(OR)为4.98,95%可信区间CI[1.58 ~ 17.35]显著相关,而年龄、BMI、某些合并症等其他因素对QTc延长的影响无统计学意义。结论:研究结果强调了与医院内使用延长qtc的非心脏药物相关的显著风险,特别是在心力衰竭患者中。未来的研究应旨在包括更大的患者群体,并采用跨多个中心的综合数据收集方法,以提高研究结果的稳健性和普遍性。
Predictive Analysis of Non-Cardiac Drug-Induced QTc Interval Prolongation: A Cross-Sectional Study.
Purpose: This study aimed to assess the real-world impacts of non-cardiac drug-induced QTc interval prolongation and identify associated risk factors in acute care settings.
Patients and methods: A cross-sectional study reviewed medical charts of 7,778 patients admitted to tertiary teaching hospitals from January 2016 to December 2022. Patients on CredibleMeds-listed QTc-prolonging non-cardiac drugs were identified, excluding those with congenital long QTc syndrome or on QTc-prolonging cardiac medications. Data collection involved reviewing medication charts and recording demographic and clinical data, including comorbidities and laboratory values. A logistic regression analysis was performed to address confounders, and known risk factors, calculating Odds Ratios (OR) and 95% confidence intervals (CI). Statistical analysis used SPSS Version 21.0, with p < 0.05 indicating significance.
Results: Out of 7,778 screened patients, 151 met the inclusion criteria. Among these, 75.5% demonstrated prolonged QTc values. The study identified 42 distinct medications associated with QT interval prolongation, categorized into six therapeutic groups. Proton pump inhibitors (PPIs) were the most common cause of non-cardiac drug-induced QTc interval prolongation, with esomeprazole representing 46.5% of the cases. Antimicrobial medications followed, with azithromycin at 9.6% and piperacillin-tazobactam at 6.1%. The multivariate analysis revealed that heart failure was significantly associated with QTc prolongation odd ratio (OR) 4.98 with 95% confidence interval CI [1.58 to 17.35], while other factors such as age, BMI, and certain comorbidities did not show a statistically significant impact.
Conclusion: The findings highlight the significant risk associated with the in-hospital administration of QTc-prolonging non-cardiac medications, particularly among patients with heart failure. Future research should aim to include a larger patient population and employ comprehensive data collection methods across multiple centers to enhance the robustness and generalizability of the findings.